GlobalData’s research indicated that, in 2024, China accounted for approximately 20% of the digital health market in the Asia Pacific (APAC), reflecting the rising demand for innovations like DeepSeek in the healthcare field.
Pratibha Thammanabhatla, a Medical Devices Analyst at GlobalData, noted, “The recent introduction of Qwen2.5-Max, Kimi k1.5, and DeepSeek demonstrates China’s expanding presence in the AI industry and its commitment to achieving technological independence. The advanced AI capabilities they offer, such as significant efficiency improvements, enhanced reasoning, and accessibility, have the potential to enhance diagnostic capabilities, provide personalized recommendations, and improve communication between patients and healthcare providers.”
Alibaba Cloud claimed that its latest Qwen2.5-Max has shown significant advantages over other AI models like Llama 3.1 405B, DeepSeek-V3, and Qwen2.5 72B when assessed using benchmark tools such as Arena-Hard, LiveBench, LiveCodeBench, and GPQA Diamond. They anticipate that advancements in post-training techniques will take the next version of Qwen2.5-Max to new heights.
Thammanabhatla concluded, “While AI has the potential to transform healthcare by enhancing efficiency and patient outcomes, challenges such as data privacy, doctor-patient relationships, and a shortage of adequately trained personnel need to be addressed for successful implementation. A collaborative approach involving stakeholders from different countries and sectors, including healthcare professionals, regulators, and data privacy experts, is crucial to overcoming these challenges and promoting wider adoption.”
